A strain of Lactobacillus rhamnosus MBP01 for preventing and treating hemorrhoids and its application

Abstract

The present invention belongs to the field of microbial technology, and specifically relates to a strain of Lactobacillus rhamnosus MBP01 and its application for preventing and treating hemorrhoids. The present invention provides the application of Lactobacillus rhamnosus MBP01 or its microecological preparation with a deposit number of GDMCC NO:64725 in the preparation of products for preventing, treating, adjuvant therapy or post-procedural care of hemorrhoids. The Lactobacillus rhamnosus MBP01 provided by the present invention can improve the weight loss trend of hemorrhoid model mice, reduce anorectal swelling, reduce the rectal coefficient of the treatment experimental group, alleviate the damage of rectal tissue, lower the levels of TNF-α, IL-2, PGE2 and NO in the treatment experiment and the levels of NO, IL-1, IL-4 in the prevention experiment, and reduce the expression of TNF-α and IL-6. Therefore, Lactobacillus rhamnosus MBP01 has certain efficacy in the treatment and prevention of hemorrhoids in mice.

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and particularly relates to a Lactobacillus rhamnosus MBP01 strain capable of preventing and treating hemorrhoids and application thereof. Background Art

[0002] Hemorrhoids are a common anorectal disease caused by congestion or congestion and swelling of the venous plexus in the anal canal or lower rectum. Bleeding, pain, anal itching and hemorrhoid prolapse may occur during defecation. The occurrence of hemorrhoids is related to many factors, including constipation, diarrhea, long-term sitting or standing, spicy food, etc. Among them, constipation is an important cause of hemorrhoids, because constipation causes dry and hard stools, which can easily damage the blood vessels and mucosa around the anus during defecation, thus causing hemorrhoids. Due to its high incidence rate and prolonged duration of treatment, it will cause great difficulties in life and mental stress to patients, and has become an important topic of continuous concern in the medical field. Preventing the occurrence of hemorrhoids, alleviating patients' pain, and improving their quality of life are important directions for the treatment of hemorrhoids.

[0003] In recent years, studies have found that probiotics can relieve patients' hemorrhoid symptoms by improving constipation, especially for patients with mild to moderate hemorrhoids. As a common probiotic, Lactobacillus rhamnosus is widely used to improve intestinal function. Patent CN112237287B provides a strain of Lactobacillus rhamnosus LR519 that can relieve constipation, and combines it with Bifidobacterium bifidum TMC3115 powder to relieve constipation. Patent CN110946913B provides a probiotic composition that assists in relieving constipation and hemorrhoid symptoms, including Lactobacillus plantarum LP45 powder, Lactobacillus acidophilus La28 powder, Lactobacillus rhamnosus LR519 powder and Bifidobacterium bifidum TMC3115 powder, which can quickly supplement probiotics to the human intestine, provide nutrients for probiotics in the intestine, and promote the rapid reproduction of probiotics in the intestine to regulate the intestinal flora environment, improve constipation, and effectively relieve the pain caused by hemorrhoids.

[0004] Existing technologies show that Lactobacillus rhamnosus can colonize and reproduce in the intestines, help maintain the balance of intestinal flora, secrete beneficial substances such as lactic acid, promote food digestion and absorption, enhance the function of the gastrointestinal mucosal barrier, reduce the penetration of harmful substances, and protect the intestines from damage. This is crucial for preventing intestinal inflammation and maintaining intestinal health. Research on probiotics in improving intestinal function has initially shown results. At present, there is still a need to develop a probiotic that can effectively prevent and treat hemorrhoids. Summary of the invention

[0005] In order to solve the above problems, the present invention provides a strain of Lactobacillus rhamnosus MBP01 and its application for preventing and treating hemorrhoids. The present invention provides the application of Lactobacillus rhamnosus MBP01 or its microecological preparation with a deposit number of GDMCC NO: 64725 in the preparation of a medicine for preventing, treating, adjuvant treatment or post-procedural care of hemorrhoids. The Lactobacillus rhamnosus MBP01 provided by the present invention can improve the weight loss trend of hemorrhoid model mice, reduce anorectal swelling, reduce the rectal coefficient of the treatment experimental group, alleviate the damage of rectal tissue, lower the levels of TNF-α, IL-2, PGE2 and NO in the treatment experiment and the levels of NO, IL-1, IL-4 in the prevention experiment, and reduce the expression of TNF-α and IL-6. Therefore, Lactobacillus rhamnosus MBP01 has a certain effect on the treatment and prevention of hemorrhoids in mice.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0007] In a first aspect, the present invention provides a Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ), the rhamnosus Lactobacillus is rhamnosus Lactobacillus MBP01, which was deposited in Guangdong Provincial Microbiological Culture Collection Center on June 5, 2024, with the deposit number GDMCC NO: 64725.

[0008] In a second aspect, the present invention provides a microecological preparation of the above-mentioned Lactobacillus rhamnosus, wherein the microecological preparation comprises one or more of a culture, a culture extract, a bacterial cell, a fermentation broth, and a freeze-dried powder of Lactobacillus rhamnosus MBP01.

[0009] In a third aspect, the present invention provides the use of Lactobacillus rhamnosus or its microecological preparation in the preparation of products for the prevention, treatment, auxiliary treatment or prognostic care of hemorrhoids. The Lactobacillus rhamnosus is Lactobacillus rhamnosus MBP01, and its preservation number is GDMCC NO:64725.

[0010] Specifically, the microecological preparation includes one or more of the culture, culture extract, bacteria, fermentation liquid and freeze-dried powder of Lactobacillus rhamnosus MBP01.

[0011] Specifically, the products include health products or medicines.

[0012] Specifically, the dosage form of the drug includes a dosage form for gastrointestinal administration or a dosage form for parenteral administration.

[0013] Preferably, the dosage forms for administration via the gastrointestinal tract include, but are not limited to, tablets, powders, granules, solutions, capsules, emulsions, suspensions, and oils.

[0014] Preferably, the non-gastrointestinal administration dosage forms include injection dosage forms, respiratory tract administration dosage forms, skin administration dosage forms, mucosal administration dosage forms and cavity administration dosage forms.

[0015] In a fourth aspect, the present invention provides a drug for preventing, treating, assisting in the treatment or post-treatment care of hemorrhoids, wherein the drug comprises Lactobacillus rhamnosus MBP01, and the Lactobacillus rhamnosus MBP01 has a preservation number of GDMCC NO:64725.

[0016] Specifically, the drug contains at least 1×10 7 CFU / dose of Lactobacillus rhamnosus MBP01.

[0017] Preferably, the drug contains 1×10 7 -1×10 12 CFU / dose of Lactobacillus rhamnosus MBP01.

[0018] More preferably, the drug contains 1×10 7 -1×10 9 CFU / dose of Lactobacillus rhamnosus MBP01.

[0019] Still more preferably, the drug contains 1×10 7 -1×10 8 CFU / dose or 1×10 8 -1×10 9 CFU / dose of Lactobacillus rhamnosus MBP01.

[0020] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0021] Preferably, the pharmaceutically acceptable excipients include, but are not limited to, one or more of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, and buffers.

[0022] In a fifth aspect, the present invention further provides a food containing Lactobacillus rhamnosus MBP01, wherein the Lactobacillus rhamnosus MBP01 has a preservation number of GDMCC NO:64725.

[0023] Specifically, the food includes but is not limited to compressed candy, soy milk, yogurt, canned food, biscuits, chocolate, cakes, cream, cheese, sour cream, milk powder, ice cream, popsicles, jam, puree, candied fruit, preserved fruit, bread, egg rolls, protein drinks, solid drinks, lactic acid bacteria drinks, plant protein drinks, carbonated drinks, coffee or puffed food.

[0024] In a sixth aspect, the present invention further provides a health product containing Lactobacillus rhamnosus MBP01, wherein the Lactobacillus rhamnosus MBP01 has a preservation number of GDMCC NO:64725.

[0025] Specifically, the dosage forms of health care products include tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0026] Preferably, the health care product also includes nutritional additives that are nutritionally acceptable.

[0027] Further preferably, the nutritional additives include one or more of dietary fiber, prebiotics, protein, lipids, minerals and vitamins.

[0028] In a seventh aspect, the present invention provides an application of the above-mentioned health care product, food or medicine, which comprises administering an effective amount of the health care product, food or medicine to a subject.

[0029] Specifically, the subject is a mammal.

[0030] Preferably, the subject is a human.

[0031] The beneficial effects of the present invention are:

[0032] (1) The present invention provides a Lactobacillus rhamnosus MBP01, which was deposited in Guangdong Microbiological Culture Collection Center on June 5, 2024, with a deposit number of GDMCC NO: 64725.

[0033] (2) The Lactobacillus rhamnosus MBP01 provided by the present invention can improve the weight loss trend of hemorrhoid model mice, reduce anorectal swelling, reduce the rectal coefficient of the treatment experimental group, alleviate rectal tissue damage, down-regulate the levels of TNF-α, IL-2, PGE2 and NO in the treatment experiment and the levels of NO, IL-1, IL-4 in the prevention experiment, and reduce the expression of TNF-α and IL-6. Therefore, Lactobacillus rhamnosus MBP01 has a certain effect on the treatment and prevention of hemorrhoids in mice.

[0034] Collection Instructions

[0035] Strain Name: Lacticaseibacillus rhamnosus MBP01 ;

[0036] Deposit number: GDMCC NO:64725;

[0037] Category naming: Lacticaseibacillus rhamnosus ;

[0038] Deposit date: June 5, 2024;

[0039] Depository: Guangdong Microbiological Culture Collection Center;

[0040] Address of the preservation unit: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 Figure 2 is the weight change of mice; Figure A is the weight change data of the prevention experimental group; Figure B is the weight change data of the treatment experimental group.

[0042] Figure 2 is the rectal coefficient; in the figure, A is the rectal coefficient of the prevention experimental group; B is the rectal coefficient of the treatment experimental group; in the figure, the same lowercase letters ae indicate no significant difference between the two groups, and different lowercase letters indicate a significant difference between the two groups P < 0.05.

[0043] Figure 3 The rectal tissue sections of mice were stained; A is the rectal tissue section of the prevention experimental group; B is the rectal tissue section of the treatment experimental group.

[0044] Figure 4 is the mRNA expression of IL-6 and TNF-α in the rectum of mice; in the figure, A is the mRNA expression of TNF-α in the prevention experimental group; B is the mRNA expression of TNF-α in the treatment experimental group; C is the mRNA expression of IL-6 in the prevention experimental group; D is the mRNA expression of IL-6 in the treatment experimental group; in the figure, the same lowercase letters in ae indicate no significant difference between the two groups, and different lowercase letters indicate significant difference between the two groups P < 0.05.

[0045] Figure 5 Serum cytokine levels of mice in the prevention group; in the figure, A represents NO content; B represents VEGF content; C represents EGF content; D represents PEG2 content; E represents IL-1β content; F represents IL-2 content; G represents TNF-α content; H represents IL-6 content; I represents IL-4 content; The same lowercase letters in ae in the figure indicate no significant difference between the two groups, and different lowercase letters indicate significant difference between the two groups P < 0.05.

[0046] Figure 6 is the serum cytokine level of mice in the treatment group; in the figure, A represents NO content; B represents VEGF content; C represents EGF content; D represents PEG2 content; E represents IL-1β content; F represents IL-2 content; G represents TNF-α content; H represents IL-6 content; I represents IL-4 content; in the figure, the same lowercase letters ae indicate no significant difference between the two groups, and different lowercase letters indicate significant difference between the two groups P < 0.05. DETAILED DESCRIPTION

[0047] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0048] 1. The experimental materials and reagents used in the present invention are shown in Table 1:

[0049] Table 1 Experimental materials and reagents

[0050]

[0051] 2. Experimental Animals

[0052] The present invention uses 5-week-old SPF-grade healthy male ICR mice for the experiment.

[0053] 3. Experimental strains

[0054] The strain used in the present invention is Lactobacillus rhamnosus MBP01, which is preserved in Guangdong Microbiological Culture Collection Center with a preservation number of GDMCC NO:64725.

[0055] 4. Data processing

[0056] In this experiment, the results were expressed as mean ± standard deviation (x ± S), and one-way analysis of variance was used for comparison between groups. The same lowercase letters in ae indicate no significant difference between the two groups, and different lowercase letters indicate significant difference between the two groups (P < 0.05).

[0057] Example 1 Study on the efficacy of Lactobacillus rhamnosus MBP01

[0058] 1.1 Experimental grouping and model establishment

[0059] 80 male ICR mice were randomly divided into 8 groups, 10 mice in each group. The experiment was divided into a preventive experimental group and a therapeutic experimental group.

[0060] The prevention experimental groups were: normal group, model group, MBP01 high-dose group (MBP01-H, 1×10 9 CFU / kg of Lactobacillus rhamnosus MBP01), MBP01 low-dose group (MBP01-L, 1×10 7CFU / kg of Lactobacillus rhamnosus MBP01). In the prevention experimental group, the MBP01 high-dose group and the MBP01 low-dose group were gavaged with the corresponding concentration of bacterial solution every day, and the normal group and the model group were gavaged with an equal volume of saline. Except for the normal group, the mice in the other groups were modeled with croton oil (prepared with distilled water, pyridine, ether and 6% croton oil in a ratio of 1:4:5:10) on the 15th day. The experimental period was 15 days, and the weight of the mice was recorded every other day.

[0061] Treatment experimental groups were set up as follows: model group, positive drug group (0.244 g / kg diosmin, Shanghai McLean Biochemical Technology Co., Ltd. D807472), MBP01 high-dose group (MBP01-H, 1×10 9 CFU / kg of Lactobacillus rhamnosus MBP01), MBP01 low-dose group (MBP01-L, 1×10 7 CFU / kg of Lactobacillus rhamnosus MBP01). In the treatment experimental group, all groups of mice were modeled on the first day, and the positive drug group and MBP01 group were gavaged with corresponding concentrations of drugs and bacterial solution every day; the experimental period was 15 days, and the weight of the mice was recorded every other day.

[0062] The results of the test are as follows Figure 1 As shown in the figure, in the prevention experiment, the weight of mice in all groups showed an upward trend. In the treatment experiment, the weight of mice in all groups showed a trend of first decreasing and then increasing, but the positive control group and the high- and low-dose MBP01 groups had a lower weight increase rate than the model group after the intervention of drugs and MBP01, which was because the oral gavage treatment of the bacteria group and the drug group would affect the feeding of mice.

[0063] 1.2 Determination of rectal coefficient

[0064] The mice were weighed before being killed. After being killed, the rectum of the mice was removed under sterile conditions. The tissues around the rectum were removed and washed with saline and then dried with filter paper. The rectum was weighed and the rectum coefficient was calculated according to the following formula:

[0065] ;

[0066] like Figure 2 As shown in the figure, in the prevention experiment, compared with the normal group, the anorectal coefficient of the mice in the model group was significantly increased (P < 0.05); compared with the hemorrhoid model group, the anorectal coefficient of the mice in the low- and high-dose MBP01 groups was reduced (P < 0.05). In the treatment experiment, there was no obvious trend in the rectal coefficient of the mice in all groups (P > 0.05), which was not statistically significant.

[0067] 1.3 H&E stained sections of rectal tissue

[0068] The mouse rectum was collected aseptically and fixed in paraformaldehyde tissue fixative. After the tissue samples were fixed and dehydrated, they were embedded in paraffin. The paraffin-embedded blocks were cut into 0.3 μm slices by a microtome, and then routinely dewaxed, hydrated with gradient ethanol, stained with hematoxylin for 2 minutes, differentiated with 1% hydrochloric acid ethanol for 3-5 seconds, blueed with dilute ammonia for 1-2 seconds, stained with eosin for 15 seconds, dehydrated, transparent, and sealed with neutral gum. The pathological changes of the rectal tissue were observed under an upright microscope.

[0069] H&E stained sections of rectal tissue Figure 3 . In the prevention experiment, H&E staining of the mouse rectum showed that the anorectal tissue structure of the mice in the normal group was normal, and the mucosal layer was intact. Compared with the normal group, the anorectal tissue of the mice in the model group was severely edematous, with leukocyte infiltration, degeneration and necrosis of the glandular epithelium, mucosal layer and submucosal layer, thickening of the mucosa in the inflammatory area, and severe dilation of blood vessels. Compared with the hemorrhoid model group, the anorectal mucosal layer of the mice in the MBP01 low-dose group and the MBP01 high-dose group was partially intact, and the inflammatory infiltration was reduced. In the treatment experiment, H&E staining of the rectal tissue showed that the model group had local tissue mucosal defects, a large number of inflammatory cell infiltration and tissue necrosis on the surface. Compared with the model group, the positive control group, the MBP01 low-dose group and the high-dose group had a relatively intact mucosal layer, reduced tissue necrosis, and significantly improved rectal tissue pathology.

[0070] 1.4 Determination of mRNA in mouse rectal tissue

[0071] Weigh the colon tissue of the mouse, wash it with sterile saline, and put it into a homogenizer tube. Add Trizol for homogenization to extract RNA from the mouse ileum tissue, and then use a spectrophotometer to measure the concentration and purity of the RNA extract. According to the instructions of the reverse transcription kit, the RNA extract is reverse transcribed into cDNA. After reverse transcription, prepare the cDNA reaction system in an eight-tube strip, that is, Mastermix 10μL, upstream and downstream primers 0.4μL each, template cDNA 1μL and sterile enzyme-free water 8.2μL. After the reaction system is prepared, place it on a real-time fluorescence quantitative PCR instrument for amplification detection.

[0072] TNF-α and IL-6 are the main cytokines that induce inflammatory responses. Figure 4 As shown. In the treatment experiment, the expression of TNF-α and IL-6 in the model group was significantly higher than that in the MBP01 high-dose group, MBP01 low-dose group and positive group. The data of the prevention group had no obvious trend and was not statistically significant.

[0073] 1.5 Determination of serum cytokine levels in mice

[0074] After the experimental period, whole blood was collected by orbital sampling. The blood was centrifuged (4°C, 14000r / min, 15min) after standing for half an hour at 4°C. After centrifugation, the upper serum was collected in a centrifuge tube and stored in a -80°C refrigerator. According to the instructions of the kit, ELISA reagents were used to determine the levels of tumor necrosis factor (TNF-α), mouse interleukins (IL-2, IL-4, IL-6, IL-1β), prostaglandin E2 (PGE2), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and nitric oxide (NO) in serum.

[0075] The results of the test are shown in Figure 5 In the prevention experiment, compared with the normal group, the levels of proinflammatory cytokines TNF-α, IL-2 and NO in the serum of the model group mice were significantly increased (P < 0.05). Compared with the model group, the NO, EGF, PEG2, IL-2 and TNF-a in the low-dose MBP01 group and the high-dose MBP01 group were significantly decreased (P < 0.05). The IL-6 level in the MBP01-H group was increased, and the IL-6 level in the MBP01-L group was decreased. There was no obvious trend for IL-1 and IL-4, and no statistical significance was found.

[0076] In the treatment experiment, compared with the model group, the levels of PEG2 and VEGF in the MBP01-L group were significantly decreased (P < 0.05), and the level of IL-2 was significantly increased. Compared with the model group, the levels of NO, IL-1, and IL-4 in the MBP01 group were significantly decreased (P < 0.05), while EGF, TNF-α, and IL-6 had no obvious trend in this experiment and were not statistically significant.

[0077] The present invention is to study the preventive and therapeutic effects of Lactobacillus rhamnosus MBP01 on mouse hemorrhoids, and this experiment utilizes croton oil mixed solution, pushes into the mouse anus, and successfully induces and constructs a mouse hemorrhoid anus swelling model. The mouse experimental hemorrhoid model induced by croton oil is similar to the clinical characteristics of human external hemorrhoids and internal hemorrhoids. In this study, it is found that in the treatment experiment, compared with the normal group, the anorectal coefficient of the model group mice significantly increases, and in the two experiments of treatment and prevention, tissue redness and swelling, ulceration occur in the anorectal of the hemorrhoid model group mice, and a large amount of inflammatory fluid exudates, which is similar to the clinical manifestations of human hemorrhoids, and the above phenomenon shows that the modeling is successful, and the modeling is successful in this experiment.

[0078] The fundamental cause of hemorrhoids is that the venous plexus under the mucosa of the rectum end and the skin of the anal canal is bent, resulting in the formation of soft venous masses. Therefore, the present invention uses hematoxylin and eosin staining to observe the rectum of hemorrhoid model mice pathologically. The study found that the rectal tissue mucosa of the model group mice was defective, with a large number of inflammatory cells infiltrating and tissue necrosis on the surface, thickening of the mucosa in the inflammatory area, and severe dilation of blood vessels, while the rectal tissue mucosa layer of the mice administered with MBP01 was partially intact, and the inflammatory infiltration was alleviated. At the same time, in order to better explore the rectal inflammatory reaction caused by hemorrhoids, the present invention uses PCR to measure the expression of IL-6 and TNF-α in the rectal tissue. The results show that in the treatment experiment, the expression of TNF-α and IL-6 in the model group is significantly increased, and the expression of TNF-α and IL-6 in the high and low dose groups of MBP01 is decreased compared with the model group, indicating that Lactobacillus rhamnosus MBP01 can significantly improve the anorectal tissue damage induced by croton oil mixture, reduce the inflammatory reaction of rectal tissue, and has a good therapeutic effect.

[0079] Abnormal inflammation level is another important cause of hemorrhoids, in which cytokines play a core role. Increased expression of IL-6, IL-1β, TNF-α, IL-2 and IL-4 in serum is positively correlated with inflammatory damage and the severity of inflammatory response. These inflammatory cytokines can induce local inflammatory cell infiltration and tissue damage. Inflammation is the basic defense response of the body after trauma, and the level of inflammatory factors can reflect the severity of inflammation. IL-6, IL-1β and TNF-α are all commonly used clinical inflammatory indicators, and are often used as important indicators to evaluate the degree of inflammatory response after hemorrhoid treatment. The anus is not only a body organ, but also a receptor. TRPV1 in the anorectum is mainly distributed in the connective tissue of the submucosal layer of the anal canal. After tissue damage, the H+ concentration in the inflammatory area increases, and H+ can directly activate TRPV1, directly causing nociceptive pain. At the same time, the activation of TRPV1 can induce a large amount of Ca2+ influx, causing a large amount of release of cytokines such as IL-2, IL-4, TNF-α, and prostaglandins, further causing inflammation and pain. Substance P, as a small molecule neuropeptide produced by inflammatory response, is mainly involved in the regulation of cell proliferation and differentiation in wound repair. Substance P can induce inflammatory cells to release inflammatory factors, such as IL-2, IL-4 and TNF-α, leading to the aggravation of inflammation. NO, as an important second messenger, is an endogenous vasopressin and is widely involved in regulating many pathological and physiological processes such as blood circulation, platelet activity, neurotransmission, immunity and inflammation. VEGF is the strongest known vascular permeability factor and mainly acts on the microvascular formation stage. It can stimulate the growth of endothelial cells and plays a vital role in angiogenesis and vasculogenesis. EGF and EGFR are both cytokines that play a key role in wound healing. EGF can induce the proliferation of keratinocytes and fibroblasts, promote the proliferation of endothelial cells, change the chemotaxis of cells, and induce inflammatory cells to move to the wound site. In the present study, it was found that after mice were modeled with croton oil mixture, in the prevention experiment, compared with the normal group, the levels of proinflammatory cytokines TNF-α, IL-2 and NO in the serum of the model group mice were significantly increased, compared with the model group, the NO, PEG2, IL-2, and TNF-a in the MBP01 group were significantly reduced, and in the treatment experiment, compared with the model group, the NO, IL-1, and IL-4 levels in the MBP01 group were significantly reduced. The results show that Lactobacillus rhamnosus MBP01 can reduce inflammatory response and play an anti-inflammatory role in the treatment and prevention of hemorrhoids.

[0080] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ) or its microecological preparation in the preparation of a drug for the prevention, treatment, adjuvant treatment or prognosis and care of hemorrhoids, characterized in that: The Lactobacillus rhamnosus is Lactobacillus rhamnosus MBP01, and its preservation number is GDMCC NO:64725.

2. The use according to claim 1, characterized in that: The microecological preparation comprises one or more of the culture, bacterial cells and freeze-dried powder of Lactobacillus rhamnosus MBP01.

3. The use according to claim 1, characterized in that: The dosage form of the drug includes a dosage form for administration via the gastrointestinal tract.

4. The use according to claim 3, characterized in that: The dosage forms for administration via the gastrointestinal tract include tablets, powders, granules, solutions, capsules, emulsions, suspensions, and oils.

5. A drug for the prevention, treatment, adjuvant treatment or prognostic care of hemorrhoids, characterized in that: The medicine comprises rhamnosus lactobacillus MBP01, and the preservation number of the rhamnosus lactobacillus MBP01 is GDMCC NO:64725.

6. The drug according to claim 5, characterized in that The drug contains at least 1×10 7 CFU / dose of Lactobacillus rhamnosus MBP01.

7. The drug according to claim 6, characterized in that The drug contains 1×10 7 -1×10 9 CFU / dose of Lactobacillus rhamnosus MBP01.

8. The drug according to claim 7, characterized in that The medicine also includes pharmaceutically acceptable excipients.

Images